Bioactive lipid mediators in polycystic kidney disease-Reference-Cited by-同舟云学术

Bioactive lipid mediators in polycystic kidney disease

Published:2014-06 Issue:6 Volume:55 Page:1139-1149
ISSN:0022-2275
Container-title:Journal of Lipid Research
language:en
Short-container-title:Journal of Lipid Research

Author:

Klawitter Jelena,Klawitter Jost,McFann Kim,Pennington Alexander T.,Abebe Kaleab Z.,Brosnahan Godela,Cadnapaphornchai Melissa A.,Chonchol Michel,Gitomer Berenice,Christians Uwe,Schrier Robert W.

Publisher

Elsevier BV

Subject

Cell Biology,Endocrinology,Biochemistry

Reference77 articles.

1. Survival after end-stage renal disease in autosomal dominant polycystic kidney disease: contribution of extrarenal complications to mortality;Perrone;Am. J. Kidney Dis.,2001

2. Inflammatory syndrome in chronic kidney disease: pathogenesis and influence on outcomes;Filiopoulos;Inflamm. Allergy Drug Targets.,2009

3. Oxidative stress, anti-oxidant therapies and chronic kidney disease;Small;Nephrology (Carlton).,2012

4. Cardiac magnetic resonance assessment of left ventricular mass in autosomal dominant polycystic kidney disease;Perrone;Clin. J. Am. Soc. Nephrol.,2011

5. Cardiac involvement in autosomal-dominant polycystic kidney disease: a hypertensive heart disease;Bardají;Clin. Nephrol.,2001

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Statin therapy in patients with early-stage autosomal dominant polycystic kidney disease: Design and baseline characteristics;Contemporary Clinical Trials;2024-02

2. The physiological and pathological properties of Mead acid, an endogenous multifunctional n-9 polyunsaturated fatty acid;Lipids in Health and Disease;2023-10-14

3. Renoprotective Effect of TP0472993, a Novel and Selective 20-Hydroxyeicosatetraenoic Acid Synthesis Inhibitor, in Mouse Models of Renal Fibrosis;Journal of Pharmacology and Experimental Therapeutics;2023-05-04

4. Discovery of Novel Pyrazolylpyridine Derivatives for 20-Hydroxyeicosatetraenoic Acid Synthase Inhibitors with Selective CYP4A11/4F2 Inhibition;Journal of Medicinal Chemistry;2022-11-01

5. A Systematic Review of Reported Outcomes in ADPKD Studies;Kidney International Reports;2022-09